Author(s)

Wenfei Chen, Zaiyou Tan^*, Lin Luo, Ruisi Yan, Hui Yang, Chunmei Tong, Yuqing Huang, Tingyu Huang, Yang Yang, Ruonan Wang

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.

Objective: To develop the characterization of the polymorphs and the best preparation method of two forms of the title compound (SU2162). After SU2162 was prepared in accordance with the patent process, the crystal form I was recrystallized by ethyl acetate and the crystal form II was obtained by the recrystal in acetone. And the two crystal forms were characterized with differential scanning calorimetry (DSC) and X-ray powder diffraction (PXRD). The melting point of crystal form I (triclinic) is at 158°C, and the melting point of crystal form II (monoclinic) is at 163°C. The PXRD studies of the two crystalline samples indicate that they have the distinct diffraction patterns. The method herein can be stably prepared for the two crystal forms of the title compound.

SU2162, Crystal Form, DSC, PXRD

Chen, W. , Tan, Z. , Luo, L. , Yan, R. , Yang, H. , Tong, C. , Huang, Y. , Huang, T. , Yang, Y. and Wang, R. (2015) Preparation and Characterization of Two Polymorphs of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.1^3,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162) with PXRD and DSC. Advances in Materials Physics and Chemistry, 5, 16-21. doi: 10.4236/ampc.2015.51003.